Biểu đồ giá cổ phiếu ONC
ONC Giá
BeOne Medicines AG
$312.12
-1.53%
$-4.87
Khi đóng cửa: May 08, 16:00:00 GMT-4
$301.47
-3.41%
$-10.64
Phiên sau giờ: May 08, 20:00:00 GMT-4
Quay lại
BeOne Medicines AG (ONC) Giá
Thống kê chính
Giá đóng cửa trước
$317
Giá mở cửa
$317
Phạm vi ngày
$301.47 - $318.03
Phạm vi 52 tuần
$218.31 - $385.22
Khối lượng
207.4K
Khối lượng trung bình
230.1K
Tỷ suất cổ tức
--
EPS (TTM)
4.42
Vốn hóa thị trường
$28.6B
BeOne Medicines Ltd. là gì?
BeOne Medicines AG is a CH-based company operating in Biotechnology industry. The company is headquartered in Basel, Basel-Stadt and currently employs 11,825 full-time employees. The company went IPO on 2016-03-02. BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. The company is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
